Burcon Completes Equity Offering Raises $5.75 Million
VANCOUVER, British Columbia, Nov. 23, 2012 (GLOBE NEWSWIRE) -- /NOT FOR
DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED
Burcon NutraScience Corporation (TSX:BU) (Nasdaq:BUR) ("Burcon" or the
"Corporation") is pleased to announce it has closed its previously announced
equity offering and has issued 1,437,500 common shares at a price of $4.00 per
share for total gross proceeds of $5.75 million (the "Offering").
The net proceeds of the Offering will be used for continued commercialization
of Burcon's uniquely soluble and clean-tasting Peazazz™ pea protein, CLARISOY™
soy protein and for general working capital purposes, all as more particularly
set out in the Final Prospectus.
"We are pleased with the strong response we received from the market,
particularly at a time when access to capital is difficult. Completion of
this financing is an important milestone in our development plan and will
allow us to focus more on our Peazazz pea protein," said Johann F. Tergesen,
President and Chief Operating Officer, adding, "Protein ingredients continue
to benefit from a strong global trend towards health and wellness in food and
beverages.We are looking forward to near-term commercial advancements for our
CLARISOY^™ soy protein isolate technology and our Peazazz pea protein as
NCP Northland Capital Partners Inc. as lead agent and Raymond James Ltd.
(together the "Agents") received a commission equal to 6% of the gross
proceeds of the Offering and compensation options entitling the Agents to
purchase up to 57,500 common shares (equal to 4% of the common shares sold
pursuant to the Offering).Each compensation option is exercisable to acquire
one common share of the Corporation at an exercise price of $4.00 per share
any time before and including May 23, 2014.
This press release is not an offer to sell or the solicitation of an offer to
buy the securities in any jurisdiction in which such offer, solicitation or
sale would be unlawful prior to qualification or registration under the
securities laws of such jurisdiction. The securities issued in the Offering
have not been, nor will they be, registered under the United States Securities
Act of 1933, as amended, and such securities may not be offered or sold within
the United States absent registration or an applicable exemption from U.S.
About Burcon NutraScience
Burcon is a leader in nutrition, health and wellness in the field of
functional, renewable plant proteins. Since 1999, Burcon has developed a
portfolio of composition, application, and process patents originating from
our core protein extraction and purification technology.We have developed
CLARISOY™ soy protein, which offers clarity and complete protein nutrition for
low pH beverage systems; Peazazz™ a uniquely soluble and clean-tasting pea
protein and Puratein®, Supertein™ and Nutratein™ canola protein isolates with
unique functional and nutritional attributes.Our team of highly specialized
scientists and engineers work from our private research facility to develop
and optimize environmentally sound technologies. To date, our patent portfolio
consists of 215 issued patents in various countries, including 35 issued U.S.
patents, and in excess of 395 additional pending patent applications, 77 of
which are U.S. patent applications.
CLARISOY™ is under license from Archer Daniels Midland Company.
CLARISOY™ is a trademark of Archer Daniels Midland Company.
ON BEHALF OF THE BOARD OF DIRECTORS
"Johann F. Tergesen"
Johann F. Tergesen
President and Chief Operating Officer
The TSX has not reviewed and does not accept responsibility for the adequacy
of the content of the information contained herein. This press release
contains forward-looking statements or forward-looking information.
Forward-looking statements or forward-looking information involve risks,
uncertainties and other factors that could cause actual results, performances,
prospects and opportunities to differ materially from those expressed or
implied by such forward-looking statements. All statements other than
statements of historical fact included in this release are forward-looking
statements, including, without limitation, statements regarding the timing and
use of proceeds of the Offering. There can be no assurance that such
statements will prove to be accurate and actual results and future events
could differ materially from those anticipated in such statements or
information. Important factors that could cause actual results to differ
materially from Burcon's plans and expectations include the actual results of
marketing activities, adverse general economic, market or business conditions,
regulatory changes and other risks and factors detailed herein and from time
to time in the filings made by Burcon with securities regulators and stock
exchanges, including in the section entitled "Risk Factors" in Burcon's annual
information form dated June 25, 2012.Any forward-looking statement or
information only speaks as of the date on which it was made and, except as may
be required by applicable securities laws, Burcon disclaims any intent or
obligation to update any forward-looking statement, whether as a result of new
information, future events or otherwise. Although Burcon believes that the
assumptions inherent in the forward-looking statements are reasonable,
forward-looking statements are not guarantees of future performance and
accordingly undue reliance should not be put on such.
CONTACT: For more information, please contact:
Michael Kirwan, Director, Corporate Development
Burcon NutraScience Corporation
(604) 733-0896 / (888) 408-7960 toll-free
Press spacebar to pause and continue. Press esc to stop.